Cordyceps Sunshine Biotech Holdings (RAJAF) Equity Average (2021 - 2025)

Cordyceps Sunshine Biotech Holdings' Equity Average history runs 5 years deep, the most recent figure standing at -$455047.0 for Q4 2025.

• In Q4 2025, Equity Average fell 72.58% year-over-year to -$455047.0; the TTM figure through Dec 2025 stood at -$455047.0 (down 72.58% YoY), while the FY2025 annual figure was -$455047.0, down 72.58% from the prior year.
• Equity Average was -$455047.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, down from -$263669.5 in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$144312.5 in Q4 2021 to a low of -$613573.5 in Q4 2022.
• Historically, Equity Average has averaged -$368517.8 across 5 years, with a median of -$359358.2 in 2024.
• The sharpest annual moves came in 2022 and 2023: Equity Average sank 325.17% in 2022, then surged 72.72% in 2023.
• A 5-year view of Equity Average shows it stood at -$144312.5 in 2021, then tumbled by 325.17% to -$613573.5 in 2022, then soared by 72.72% to -$167367.5 in 2023, then tumbled by 57.54% to -$263669.5 in 2024, then tumbled by 72.58% to -$455047.0 in 2025.
• The last three Equity Average figures came in at -$455047.0 (Q4 2025), -$263669.5 (Q4 2024), and -$167367.5 (Q4 2023), per Business Quant data.